{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-21-036074","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2021-07-08T23:59:59+00:00","discovered_at":"2026-05-14T18:04:18.961891+00:00","generated_at":"2026-06-30T06:37:04.029707+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Ovid Therapeutics President/CMO resigns; CEO added as President; new director appointed","bullets":["Dr. Amit Rakhit resigns as President and CMO effective Aug 27, 2021; will join Scientific & Clinical Advisory Board.","Resignation not due to disagreement with company on operations, policies, or financial matters.","CEO Jeremy M. Levin appointed President in addition to Chairman and CEO roles, effective upon Rakhit's departure.","Robert Michael Poole appointed Class I director effective July 9, 2021, term until 2024 annual meeting.","Poole entitled to standard non-employee director cash and equity compensation per company policy."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-21-036074","json":"https://secwatch.observer/filing/0001564590-21-036074.json","markdown":"https://secwatch.observer/filing/0001564590-21-036074.md","text":"https://secwatch.observer/filing/0001564590-21-036074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/ovid-8k_20210708.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-30T06:37:04.029707+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"85915a27c0","claim":"Jeremy M. Levin was appointed as President at Ovid Therapeutics Inc..","evidence_excerpt":"the Company’s Board of Directors (the “Board”) appointed Dr. Jeremy M. Levin as President of the Company, in addition to his current duties as Chairman of the Board and Chief Executive Officer of the Company, effective upon the Officer Resignation.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President"}],"fact_type":"executive_change"},{"claim_id":"d59365ed62","claim":"Robert Michael Poole was appointed as Class I director at Ovid Therapeutics Inc..","evidence_excerpt":"the Board appointed Dr. Robert Michael Poole as a Class I director of the Company, effective July 9, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"},{"claim_id":"e411afb316","claim":"Dr. Amit Rakhit resigned as President and Chief Medical Officer at Ovid Therapeutics Inc..","evidence_excerpt":"Dr. Amit Rakhit, President and Chief Medical Officer of Ovid Therapeutics Inc. (the “Company”), notified the Company of his resignation from such positions with the Company effective August 27, 2021","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1636651/000156459021036074/0001564590-21-036074-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"President and Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}